Q312: Biotech on a roll

Walter Yang

Biotech continued to outperform the broader markets, with the BioCentury 100 Index up 7% and the NASDAQ Biotechnology Index up 10% in 3Q12 versus a 6% rise in the S&P 500. Excluding partnership monies, the industry raised (mostly from debt and follow-on offerings)

Stock market performance

In 3Q12, the BioCentury 100 was up 7% and the NASDAQ Biotechnology Index was up 10%.

Notable 3Q12 deals

IPOs			
Company (lead underwriters)	Amount raised (\$ millions)	Change in stock price since offer	Date completed
Durata (BofA Merrill Lynch; Credit Suisse)	77.6	4%	19-Jul
Hyperion (Leerink; Cowen)	57.5	6%	26-Jul
PharmaEngine (MasterLink)	31.7	108%	18-Sep
Clinigen (Numis)	16.2	10%	19-Sep

Venture capital			
Company (lead investors)	Amount raised (\$ millions)	Round number	Date closed
CureVac (dievini Hopp)	105	4	18-Sep
bluebird bio (Deerfield; RA Capital; Ramius) ^a	60	4	25-Jul
CardioDx (Temasek)	58	6	27-Aug
Onconova ^b	50	ND	13-Aug
Relypsa ^{b,c}	50	3	10-Aug
Histogenics (Sofinnova)	49	1	24-Jul
Foundation Medicine ^b	43	2	20-Sep
Agile Therapeutics (Aisling)	40	3	19-Jul

Mergers and acquisitions			
Target	Acquirer	Value ^d (\$ millions)	Date announced
Elevation Pharmaceuticals	Dainippon Sumitomo	430	31-Aug
Complete Genomics	BGI-Shenzhen	118	17-Sep
Callisto Pharmaceuticals	Synergy Pharmaceuticals	117	20-Jul
CNS Therapeutics	Covidien	100	24-Sep

Licensing/collaboration			
Researcher	Investor	Value ^d (\$ millions)	Deal description
Molecular Partners	Allergan	1,463	Rights to preclinical wet age-related macular degeneration compound MPO260; three options to license designed ankyrin repeat proteins (DARPs) in ophthalmology
Genmab	Johnson & Johnson	1,135	Rights to develop and commercialize cancer product daratumumab (HuMax-CD38), a human monoclonal antibody (mAb) against CD38 in phase 1/2
MacroGenics	Servier	1,100	Option to license rights to preclinical mAbs against three undisclosed cancer targets outside North America, Japan, Korea and India
Symphogen	Merck KGaA	623	Rights to phase 2 cancer product Sym004, a combination of two anti-EGFR mAbs against two distinct epitopes
Onconova	Baxter	565	European rights to commercialize rigosertib, a dual inhibitor of phosphoinositide 3-kinase and polo-like kinase 1 in phase 3 for myelodysplastic syndrome
Regulus	AstraZeneca	537	Develop and commercialize preclinical microRNA therapeutics against three targets focused on cardiovascular and metabolic diseases and cancer

^aNew investors. ^bLead investors not disclosed. ^cRaised 49.7 million of a planned 80 million round. ^dValues include milestones.

Source: BCIC: BioCentury Online Intelligence.

\$13 billion last quarter—the fourth highest of any quarter since 2000. Only four companies completed initial public offerings (IPOs). About \$1.8 billion was raised by private biotech, up from \$1.4 billion in 2Q12 and \$1.4 billion a year ago.

Global biotech industry financing

Excluding partnerships, biotech raised \$13 billion.

Source: BCIC: BioCentury Online Intelligence, Burrill & Co. PIPEs, private investments in public equity.

Global biotech initial public offerings

IPOs continue to trickle in, with only four companies raising \$183.1 million.

	3Q11	4Q11	1Q12	2Q12	3Q12
Americas	2	2	4	2	2
Europe	0	0	2	0	1
Asia-Pacific	1	3	1	0	1

Table indicates number of IPOs. Source: BCIC: BioCentury Online Intelligence.

Global biotech venture capital investment

Private biotech raised \$1.7 billion in 3Q12, up from \$1.4 billion a year ago.

	3Q11	4Q11	1Q12	2Q12	3Q12
Americas	68	59	65	65	49
Europe	26	31	32	30	18
Asia-Pacific	4	3	0	4	1

Table indicates number of venture capital investments and includes rounds where the amount raised was not disclosed.

Source: BCIC: BioCentury Online Intelligence.

Walter Yang is Research Director at BioCentury.